journal article·2023-04-15Open access

Oral Health and Use of Novel Transbuccal Drug Delivery Systems in Patients with Alzheimer’s and Parkinson’s Disease: A Review

Michele Basilicata, Piergiorgio Grillo, Alvise Tancredi, Adolfo Di Fiore, Patrizio Bollero, Alessandro Stefani, Tommaso Schirinzi

Applied Sciences· Volume 13· Issue 8

Abstract

Neurodegenerative disorders, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), are common age-related diseases responsible for high disability. Disease-modifying treatments for AD and PD are still lacking, but symptomatic therapies are available, although limited by difficult administration and patients’ scarce compliance at later disease stages. Transbuccal Drug Delivery Systems (TDDSs) include chemical-physics biotechnologies and mechatronic approaches, allowing drug delivery via the transbuccal route, a strategy that may theoretically overcome the limitations imposed by conventional oral administration. In this review, we provided a snapshot of TDDSs, their mechanism of action, the existing subtypes, and their potential application in PD and AD patients. We found a variety of TDDSs, including tablets, solutions, sprays, patches, and the more sophisticated “mechatronic” IntelliDrug and OraFuse devices using a system of pumps and valves for continuous drug release. Several trials have been conducted either on models or patients to test the safety and efficacy of the antidementia and antiparkinsonian agents delivered by TDDSs, which produced encouraging results that suggest future application on a larger scale. Moreover, oral health has emerged as a fundamental prerequisite for the successful use of TDDSs. Accordingly, greater attention to oral hygiene is now due in patients with neurodegenerative disease.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Parkinson's Disease Mechanisms and Treatments · Neurological disorders and treatments · Botulinum Toxin and Related Neurological Disorders

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

UOSD Special Care Dentistry, Department of Experimental Medicine and Surgery, University of Roma Tor Vergata, 00133 Rome, Italy

Unit of Neurology, Department of Systems Medicine, University of Roma Tor Vergata, 00133 Rome, Italy

Department of Brain and Behavioral Sciences, University of Pavia, 27100 Pavia, Italy

UOSD Special Care Dentistry, University of Rome Tor Vergata, 00133 Rome, Italy

Department of Neurosciences, School of Dentistry, Section of Prosthodontics and Digital Dentistry, University of Padova, 35121 Padova, Italy

UOSD Special Care Dentistry, Department of Systems Medicine, University of Roma Tor Vergata, 00133 Rome, Italy

Parkinson Centre, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy

References (94)

Show source-provided references
2. Jellinger, K.A. (2011). Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders, Wiley Blackwell Publisher. [2nd ed.].
3. Parkinson Disease10.1111/ene.14108 ↗
4. The Genetics of Parkinson Disease10.1016/j.arr.2017.12.007 ↗
5. Alzheimer’s Disease10.1016/S0140-6736(20)32205-4 ↗
6. Parkinson’s Disease: Etiopathogenesis and Treatment10.1136/jnnp-2019-322338 ↗
7. Alzheimer’s Disease10.1055/s-2006-951622 ↗
8. A Century of Alzheimer’s Disease10.1126/science.1132814 ↗
9. Neuroscience: Alzheimer’s Disease10.1038/461895a ↗
10. Alzheimer’s Disease10.1111/ene.13439 ↗
11. Mumtaz, S., Rana, J.N., Choi, E.H., and Han, I. (2022). Microwave Radiation and the Brain: Mechanisms, Current Status, and Future Prospects. Int. J. Mol. Sci., 23.10.3390/ijms23169288 ↗
12. Genetics and Pathogenesis of Parkinson’s Syndrome10.1146/annurev-pathmechdis-031521-034145 ↗
13. The Understanding of Parkinson’s Disease through Genetics and New Therapies10.1002/brb3.2577 ↗
14. (2023, March 04). Parkinson’s Disease: Genetics, Pathogenesis and Emerging Therapeutics|Hindawi. Available online: https://www.hindawi.com/journals/bmri/si/426914/.
15. Epidemiology of Alzheimer Disease10.1101/cshperspect.a006239 ↗
16. Alzheimer’s Disease as an Inflammatory Disease10.1515/bmc-2016-0029 ↗
17. Preventing Alzheimer’s Disease10.1126/science.1228541 ↗
18. New Perspectives on Alzheimer’s Disease10.1146/annurev.ne.09.030186.002421 ↗
19. Constipation Distinguishes Different Clinical-Biochemical Patterns in de Novo Parkinson’s Disease10.1016/j.parkreldis.2022.08.001 ↗
20. Levodopa in Parkinson’s Disease: Current Status and Future Developments10.2174/1570159X15666170510143821 ↗
21. The Immunology of Parkinson’s Disease10.1007/s00281-022-00947-3 ↗
22. Emerging Roles of Innate and Adaptive Immunity in Alzheimer’s Disease10.1016/j.immuni.2022.10.016 ↗
23. Effects of Head Trauma and Sport Participation in Young-Onset Parkinson’s Disease10.1007/s00702-021-02370-8 ↗
24. Olfactory Neuron Prokineticin-2 as a Potential Target in Parkinson’s Disease10.1002/ana.26526 ↗
25. Orofacial Function and Oral Health in Patients with Parkinson’s Disease10.1111/j.1600-0722.2010.00802.x ↗
26. Oral Health of Parkinson’s Disease Patients: A Case-Control Study
27. Evidence-Based Recommendations for the Oral Health of Patients with Parkinson’s Disease10.1007/s40120-021-00237-4 ↗
28. Increased Frequencies of Caries, Periodontal Disease and Tooth Loss in Patients with Parkinson’s Disease10.1016/j.jocn.2008.12.027 ↗
29. Salivation in Parkinson’s Disease: A Scoping Review10.1111/ger.12628 ↗
30. Subjective and Objective Halitosis among Patients with Parkinson’s Disease10.1111/ger.12293 ↗
31. Salivary Production in Parkinson’s Disease10.1002/mds.20189 ↗
32. Parkinson Disease: Systemic and Orofacial Manifestations, Medical and Dental Management10.14219/jada.archive.2009.0251 ↗
33. Chen, Y.Y., Fan, H.C., Tung, M.C., and Chang, Y.K. (2019). The Association between Parkinson’s Disease and Temporomandibular Disorder. PLoS ONE, 14.10.1371/journal.pone.0217763 ↗
34. Oral Dysbiosis and Inflammation in Parkinson’s Disease
35. Periodontal Inflammatory Disease Is Associated with the Risk of Parkinson’s Disease: A Population-Based Retrospective Matched-Cohort Study10.7717/peerj.3647 ↗
36. Update on Bacteraemia Related to Dental Procedures10.1016/j.transci.2008.06.008 ↗
37. Infective Endocarditis and Dental Procedures: Evidence, Pathogenesis, and Prevention10.2152/jmi.53.189 ↗
38. Fiorillo, L., Cervino, G., Laino, L., D’Amico, C., Mauceri, R., Tozum, T.F., Gaeta, M., and Cicciù, M. (2019). Porphyromonas Gingivalis, Periodontal and Systemic Implications: A Systematic Review. Dent. J., 7.10.3390/dj7040114 ↗
39. Franciotti, R., Pignatelli, P., Carrarini, C., Romei, F.M., Mastrippolito, M., Gentile, A., Mancinelli, R., Fulle, S., Piattelli, A., and Onofrj, M. (2021). Exploring the Connection between Porphyromonas Gingivalis and Neurodegenerative Diseases: A Pilot Quantitative Study on the Bacterium Abundance in Oral Cavity and the Amount of Antibodies in Serum. Biomolecules, 11.10.3390/biom11060845 ↗
40. Evaluation of the Association between Periodontitis and Risk of Parkinson’s Disease: A Nationwide Retrospective Cohort Study10.1038/s41598-021-96147-4 ↗
41. Increased Periodontal Pathology in Parkinson’s Disease10.1007/s00415-006-0068-4 ↗
42. Alvarenga, M.O.P., Frazão, D.R., de Matos, I.G., Bittencourt, L.O., Fagundes, N.C.F., Rösing, C.K., Maia, L.C., and Lima, R.R. (2021). Is There Any Association Between Neurodegenerative Diseases and Periodontitis? A Systematic Review. Front. Aging Neurosci., 13.10.3389/fnagi.2021.651437 ↗
43. Neurodegenerative Disorders and Periodontal Disease: Is There a Logical Connection?10.1159/000449517 ↗
44. Auerbacher, M., Gebetsberger, L., Kaisarly, D., Schmidmaier, R., Hickel, R., and Drey, M. (2022). Oral Health in Patients with Neurodegenerative and Cerebrovascular Disease: A Retrospective Study. Disabil. Rehabil.10.1080/09638288.2022.2088866 ↗
45. Rozas, N.S., Tribble, G.D., Jeter, C.B., Machida, C.A., Maier, T.J., and Said-Al-Naief, N. (2021). Oral Factors That Impact the Oral Microbiota in Parkinson’s Disease. Microorganisms, 9.10.3390/microorganisms9081616 ↗
46. Oral Health Issues and Challenges in Parkinson’s Disease10.4103/ijnpnd.ijnpnd_22_17 ↗
47. Oral Health Disorders in Parkinson’s Disease: More than Meets the Eye
48. van Vuuren, M.J., Nell, T.A., Carr, J.A., Kell, D.B., and Pretorius, E. (2020). Iron Dysregulation and Inflammagens Related to Oral and Gut Health Are Central to the Development of Parkinson’s Disease. Biomolecules, 11.10.3390/biom11010030 ↗
49. Human Buccal Mucosa as an Innovative Site of Drug Delivery10.2174/138161210790883778 ↗
50. Advances in Oral Transmucosal Drug Delivery10.1016/j.jconrel.2011.01.027 ↗
51. Homayun, B., Lin, X., and Choi, H.J. (2019). Challenges and Recent Progress in Oral Drug Delivery Systems for Biopharmaceuticals. Pharmaceutics, 11.10.3390/pharmaceutics11030129 ↗
52. Current Applications of Drug Delivery Nanosystems Associated with Antimicrobial Photodynamic Therapy for Oral Infections10.1016/j.ijpharm.2020.120078 ↗
53. Mercadante, V., Scarpa, E., de Matteis, V., Rizzello, L., and Poma, A. (2021). Engineering Polymeric Nanosystems against Oral Diseases. Molecules, 26.10.3390/molecules26082229 ↗
54. Is Nanotechnology a Boon for Oral Drug Delivery?10.1016/j.drudis.2014.04.011 ↗
55. Mucoadhesive Drug Delivery Systems
56. A Focus on Mucoadhesive Polymers and Their Application in Buccal Dosage Forms10.1016/j.jddst.2015.06.016 ↗
57. In Vivo, Ex Vivo and in Vitro Assessment of Buccal Permeation of Drugs from Delivery Systems10.1080/17425247.2020.1699913 ↗
58. A Clinical Perspective on Mucoadhesive Buccal Drug Delivery Systems10.7555/JBR.27.20120136 ↗
59. Buccoadhesive Drug Delivery Systems--Extensive Review on Recent Patents10.2174/187221108784534135 ↗
60. Alpha-Klotho in Parkinson’s Disease: A Perspective on Experimental Evidence and Potential Clinical Implications10.4103/1673-5374.335820 ↗
61. IntelliDrug Implant for Medicine Delivery in Alzheimer’s Disease Treatment10.1002/masy.200750720 ↗
62. Drug Delivery from the Oral Cavity: Focus on a Novel Mechatronic Delivery Device10.1016/j.drudis.2007.10.018 ↗
63. Recent Advancements and Patents on Buccal Drug Delivery Systems: A Comprehensive Review10.2174/1872210515666210609145144 ↗
64. Evaluation of Galantamine Transbuccal Absorption by Reconstituted Human Oral Epithelium and Porcine Tissue as Buccal Mucosa Models: Part I10.1016/j.ejpb.2008.06.025 ↗
65. (2023, January 03). Assessing the Pharmacokinetics, Safety, Tolerability and Efficacy of Continuous Oral Levodopa Via the DopaFuse® Delivery System in Parkinson’s Disease Patients—Full Text View—ClinicalTrials.Gov, Available online: https://clinicaltrials.gov/ct2/show/NCT04778176.
66. Potential Transbuccal Delivery of L-DOPA Methylester Prodrug: Stability in the Environment of the Oral Cavity and Ability to Cross the Mucosal Tissue10.3109/10717544.2014.987332 ↗
67. New Prospective in Treatment of Parkinson’s Disease: Studies on Permeation of Ropinirole through Buccal Mucosa10.1016/j.ijpharm.2012.03.022 ↗
68. Orally-Dissolving Film for Sublingual and Buccal Delivery of Ropinirole10.1016/j.colsurfb.2017.12.015 ↗
69. di Prima, G., Campisi, G., and de Caro, V. (2020). Amorphous Ropinirole-Loaded Mucoadhesive Buccal Film: A Potential Patient-Friendly Tool to Improve Drug Pharmacokinetic Profile and Effectiveness. J. Pers. Med., 10.10.3390/jpm10040242 ↗
70. Selegiline Orally Disintegrating Tablets for the Treatment of Parkinson’s Disease10.1586/14737175.5.6.705 ↗
71. Buccal Mucosal Irritation Studies of Sublingual Apomorphine Film (APL-130277) in Syrian Golden Hamsters10.4155/tde-2016-0043 ↗
72. Controlled Delivery of Apomorphine Through Buccal Mucosa, Towards a Noninvasive Administration Method in Parkinson’s Disease: A Preclinical Mechanistic Study10.1016/j.xphs.2020.05.017 ↗
73. Prolonged Delivery of Apomorphine Through the Buccal Mucosa, Towards a Noninvasive Sustained Administration Method in Parkinson’s Disease: In Vivo Investigations in Pigs10.1016/j.xphs.2020.12.010 ↗
74. A Potential Tailor-Made Hyaluronic Acid Buccal Delivery System Comprising Rotigotine for Parkinson’s Disease?10.4155/fmc.15.66 ↗
75. Logroscino, G., and Tortelli, R. (2015). Epidemiology of Neurodegenerative Diseases. Imaging Neurodegener. Disord., 3–19.10.1093/med/9780199671618.003.0001 ↗
76. Non-Thermal Plasma Directly Accelerates Neuronal Proliferation by Stimulating Axon Formation10.1038/s41598-022-20063-4 ↗
77. Advances in Buccal Drug Delivery10.1615/CritRevTherDrugCarrierSyst.v22.i3.20 ↗
78. Recent Developments in Buccal and Sublingual Delivery Systems10.1517/17425247.2012.676040 ↗
79. Parkinson’s Disease10.1016/S0140-6736(14)61393-3 ↗
80. Bioerodible Injectable Poly(Ortho Ester) for Tetracycline Controlled Delivery to Periodontal Pockets: Preliminary Trial in Humans
81. (2023, February 05). Dental Management of Parkinson’s Disease: A Case Report—ProQuest. Available online: https://www.proquest.com/openview/69ede58a766cb511b9d77a2100e83242/1?pq-origsite=gscholar&cbl=41679.
82. Oral Function as an Indexing Parameter for Mild Cognitive Impairment in Older Adults10.1111/ggi.13259 ↗
83. Spurthi, S., Sridharan, S., Hosadurga, R., Rao, R.J., Prabhu, S., Pal, P.K., Kamble, N., Rakesh, K., and Kumar, A. (2023). Effectiveness of Oral Hygiene Educational Interventional Programs on Participants with Parkinson’s Disease: A Randomized Controlled Study. Quintessence Int.
84. Improvement of Oral Function and Hygiene in Parkinson’s Disease: A Randomised Controlled Clinical Trial10.1111/joor.12924 ↗
85. Understanding the Impact of Parkinson’s Disease on Oral Health10.12968/denn.2021.17.4.184 ↗
86. Oral Health-Related Quality of Life in Patients with Parkinson’s Disease Wearing Fixed Partial Dentures—A Prospective Study
87. Oral and Nasal Microbiota in Parkinson’s Disease10.1016/j.parkreldis.2017.02.026 ↗
88. Nicholson, J.S., and Landry, K.S. (2022). Oral Dysbiosis and Neurodegenerative Diseases: Correlations and Potential Causations. Microorganisms, 10.10.3390/microorganisms10071326 ↗
89. Prostheses in Parkinson’s Disease10.1038/s41415-019-0759-8 ↗
90. Prosthodontic Considerations in Parkinson’s Disease
91. Salivary Biomarkers for the Diagnosis and Monitoring of Neurological Diseases10.1016/j.bj.2018.03.004 ↗
92. Systematic Review of MiRNA as Biomarkers in Alzheimer’s Disease10.1007/s12035-019-1500-y ↗
93. MiRNA in Parkinson’s Disease: From Pathogenesis to Theranostic Approaches10.1002/jcp.30932 ↗
94. The Role of MicroRNAs in Neurodegenerative Diseases: A Review10.1007/s10565-022-09761-x ↗